International Clinical Trial: A Randomized, Three-Cohort Study to Evaluate the Efficacy and Safety of Different Time-of-Day Administration of Serplulimab Combined with Chemotherapy as Neoadjuvant Therapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma (TD-NICE-Timing)

Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600121582) titled 'A Randomized, Three-Cohort Study to Evaluate the Efficacy and Safety of Different Time-of-Day Administration of Serplulimab Combined with Chemotherapy as Neoadjuvant Therapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma (TD-NICE-Timing)' on April 1.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Tangdu Hospital, Air Force Medical University

Condition: Esophageal squamous cell carcinoma

Intervention: Early Group:Sliburumab 4.5mg/kg + Albumin-bound paclitaxel 125mg/m2 (D1, D8) + Cisplatin 75mg/m2 (D1), all infusions completed before 12:00 Mid-day Group:Sliburumab...